Biotechnology company Moderna Inc's (Nasdaq:MRNA) vaccine against COVID-19 has 94.1% efficacy against COVID-19 and 100% efficacy against the severe form of the disease, the company announced on Monday.
The primary efficacy analysis of the Phase 3 COVE study of mRNA-1273 involving 30,000 participants included 196 cases of COVID-19, of which 30 cases were severe. All 30 cases occurred in the placebo group and none in the mRNA-1273 vaccinated group.
Moderna said that it plans to immediately request Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) and conditional approval from the European Medicines Agency (EMA).
The company has already initiated the rolling review process with the EMA, Health Canada, SwissMedic, the UK Medicines and Healthcare products Regulatory Agency (MHRA), Ministry of Health in Israel, and Health Sciences Authority in Singapore and intends to seek Prequalification (PQ) and/or Emergency Use Listing (EUL) with the World Health Organization (WHO).
Brazil's health regulator clears emergency use of Sinovac and AstraZeneca COVID-19 vaccines
England opens up its COVID-19 vaccination programme to more groups
Dr. Reddy's Receives Approval to Conduct Phase 3 Clinical Trial for Sputnik V Vaccine in India
Carbon Health Launches COVID-19 Vaccination Platform to Accelerate National Rollout
Kyruus Enables Online Scheduling for COVID-19 Vaccine Visits
China's Sinopharm says COVID-19 vaccine safe for children and teenagers
Publix and the State of Florida to Bring COVID-19 Vaccinations to Three Florida Counties
OnSolve's CodeRed used across the US for the management of information related to COVID-19 vaccine
Meijer Pharmacies to administer COVID-19 vaccines in the State of Michigan
China's CanSino Biologics COVID-19 vaccine shows high antibody levels in Russian trials
Hungary's government signs deal with China's Sinopharm for COVID-19 vaccine purchase